Who are SR-B + Epratuzumab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lumoxiti, INOTUZUMAB OZOGAMICIN, Besponsa, Besponsa, Inotuzumab ozogamicin (INO), Inotuzumab ozogamicin-dose level 1.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sr-b-epratuzumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

SR-B + Epratuzumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SR-B + Epratuzumab (SR-B + Epratuzumab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody. Area: Immunology.

phase 3 Monoclonal antibody CD22 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

SR-B + Epratuzumab (SR-B + Epratuzumab) — Charite University, Berlin, Germany. SR-B combined with epratuzumab targets B cell surface antigens to modulate immune response in autoimmune and inflammatory conditions.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
SR-B + Epratuzumab TARGET	SR-B + Epratuzumab	Charite University, Berlin, Germany	phase 3	Monoclonal antibody	CD22
Lumoxiti	MOXETUMOMAB PASUDOTOX	AstraZeneca	marketed		B-cell receptor CD22	2018-01-01
INOTUZUMAB OZOGAMICIN	INOTUZUMAB OZOGAMICIN		marketed	CD22-directed Immunoconjugate [EPC]	CD22	2017-01-01
Besponsa	inotuzumab	Pfizer	marketed	CD22-directed Immunoconjugate [EPC]	CD22	2017-01-01
Besponsa	inotuzumab-ozogamicin	Pfizer	marketed	Antibody-drug conjugate (ADC)	CD22	2017-01-01
Inotuzumab ozogamicin (INO)	Inotuzumab ozogamicin (INO)	Charite University, Berlin, Germany	marketed	Antibody-drug conjugate (ADC)	CD22
Inotuzumab ozogamicin-dose level 1	Inotuzumab ozogamicin-dose level 1	Pfizer	marketed	Antibody-drug conjugate (ADC)	CD22

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody class)

Pfizer · 7 drugs in this class
argenx · 7 drugs in this class
Johnson & Johnson · 2 drugs in this class
German CLL Study Group · 2 drugs in this class
Amgen · 2 drugs in this class
Hoffmann-La Roche · 2 drugs in this class
Brii Biosciences Limited · 2 drugs in this class
Alexion Pharmaceuticals, Inc. · 2 drugs in this class
Biotest · 2 drugs in this class
Fondazione Italiana Linfomi - ETS · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SR-B + Epratuzumab — Competitive Intelligence Brief. https://druglandscape.com/ci/sr-b-epratuzumab. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing